Abstract
Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (
| Original language | English |
|---|---|
| Pages (from-to) | 565-573 |
| Number of pages | 9 |
| Journal | Supportive Care in Cancer |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2013 |
Fingerprint
Keywords
- AC-containing chemotherapy
- Breast cancer
- CINV
- Dexamethasone
- Meta-analysis
- Palonosetron
ASJC Scopus subject areas
- Oncology
Cite this
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy : Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. / Celio, Luigi; Bonizzoni, Erminio; Bajetta, Emilio; Sebastiani, Silvia; Perrone, Tania; Aapro, Matti S.
In: Supportive Care in Cancer, Vol. 21, No. 2, 02.2013, p. 565-573.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy
T2 - Meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials
AU - Celio, Luigi
AU - Bonizzoni, Erminio
AU - Bajetta, Emilio
AU - Sebastiani, Silvia
AU - Perrone, Tania
AU - Aapro, Matti S.
PY - 2013/2
Y1 - 2013/2
N2 - Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (
AB - Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (
KW - AC-containing chemotherapy
KW - Breast cancer
KW - CINV
KW - Dexamethasone
KW - Meta-analysis
KW - Palonosetron
UR - http://www.scopus.com/inward/record.url?scp=84874115358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874115358&partnerID=8YFLogxK
U2 - 10.1007/s00520-012-1558-9
DO - 10.1007/s00520-012-1558-9
M3 - Article
C2 - 22869054
AN - SCOPUS:84874115358
VL - 21
SP - 565
EP - 573
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 2
ER -